NeuroSense Therapeutics Ltd. NRSN
Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026
NeuroSense Therapeutics Ltd. (NRSN) is a healthcare company listed in the US with a market value of about $3M.
Its overall Stock Analiz score is 0.2 out of 5 (weak). The strongest part is track record (1/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -159%.
About NeuroSense Therapeutics
NeuroSense Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. It was profitable in 0 of the last 7 years in our data.
Score: 0.2 / 5
Checks passed
- ROE above 15%
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — |
| Net income | -$11M | -$10M | -$10M | -$10M | -$4M | -$3M | -$1M |
| Free cash flow | -$8M | -$10M | -$8M | -$8M | -$2M | -$704000 | -$589000 |
| EPS (diluted) | $-5.86 | $-5.38 | $-5.33 | $-5.53 | $-2.13 | $-1.49 | $-0.64 |
| Net margin | — | — | — | — | — | — | — |
| ROIC | — | -294.5% | — | -142.7% | -40.7% | -346.2% | -106.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does NeuroSense Therapeutics pay a dividend?
Not currently.
Is NeuroSense Therapeutics a good stock to buy?
We do not give buy or sell advice. NeuroSense Therapeutics scores 0.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.